Pazdur R - Search Results

1

Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes.

Kaminskas E, Farrell A, Abraham S, Baird A, Hsieh LS, Lee SL, Leighton JK, Patel H, Rahman A, Sridhara R, Wang YC, Pazdur R; FDA. Kaminskas E, et al. Among authors: pazdur r. Clin Cancer Res. 2005 May 15;11(10):3604-8. doi: 10.1158/1078-0432.CCR-04-2135. Clin Cancer Res. 2005. PMID: 15897554 Clinical Trial.

2

Phase I trial of sulindac plus 5-fluorouracil and levamisole: potential adjuvant therapy for colon carcinoma.

Sinicrope FA, Pazdur R, Levin B. Sinicrope FA, et al. Among authors: pazdur r. Clin Cancer Res. 1996 Jan;2(1):37-41. Clin Cancer Res. 1996. PMID: 9816087 Clinical Trial.

3

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.

Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G, Pazdur R. Bross PF, et al. Among authors: pazdur r. Clin Cancer Res. 2001 Jun;7(6):1490-6. Clin Cancer Res. 2001. PMID: 11410481

4

Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.

Cohen MH, Johnson JR, Li N, Chen G, Pazdur R. Cohen MH, et al. Among authors: pazdur r. Clin Cancer Res. 2002 Mar;8(3):665-9. Clin Cancer Res. 2002. PMID: 11895893

5

Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.

Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, Benson K, Leighton J, Kim SK, Wood R, Rothmann M, Chen G, U KM, Staten AM, Pazdur R. Cohen MH, et al. Among authors: pazdur r. Clin Cancer Res. 2002 May;8(5):935-42. Clin Cancer Res. 2002. PMID: 12006504

6

Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.

Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G, Rahman A, Chen G, Staten A, Griebel D, Pazdur R. Dagher R, et al. Among authors: pazdur r. Clin Cancer Res. 2002 Oct;8(10):3034-8. Clin Cancer Res. 2002. PMID: 12374669 Clinical Trial.

7

Gleevec for the treatment of chronic myelogenous leukemia: US. Food and Drug Administration regulatory mechanisms, accelerated approval, and orphan drug status.

Cohen MH, Moses ML, Pazdur R. Cohen MH, et al. Among authors: pazdur r. Oncologist. 2002;7(5):390-2. doi: 10.1634/theoncologist.7-5-390. Oncologist. 2002. PMID: 12401900 Free article.

8

U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid.

Cohen MH, Dagher R, Griebel DJ, Ibrahim A, Martin A, Scher NS, Sokol GH, Williams GA, Pazdur R. Cohen MH, et al. Among authors: pazdur r. Oncologist. 2002;7(5):393-400. doi: 10.1634/theoncologist.7-5-393. Oncologist. 2002. PMID: 12401901 Free article.

9

Postmarketing re-evaluation of irinotecan plus 5-fluorouracil/leucovorin for first-line treatment of metastatic colorectal cancer.

Chico IM, Pazdur R. Chico IM, et al. Among authors: pazdur r. Clin Colorectal Cancer. 2002 May;2(1):11-2. doi: 10.1016/S1533-0028(11)70495-9. Clin Colorectal Cancer. 2002. PMID: 12453329 No abstract available.

10

FDA drug approval summaries: fulvestrant.

Bross PF, Cohen MH, Williams GA, Pazdur R. Bross PF, et al. Among authors: pazdur r. Oncologist. 2002;7(6):477-80. doi: 10.1634/theoncologist.7-6-477. Oncologist. 2002. PMID: 12490735 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

606 results

Search Page

Filters